Erythropoietin, a novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitus Saher Hamed et al Wound Repair and Regeneration; Early View Quote: Developing a new drug is expensive: the cost of going from bench to bedside is about $US1 billion. Therefore, the repurposing of an approved drug is potentially rewarding because it expands the drug’s existing therapeutic profile and preempts additional development costs
Read the original:
Erythropoietin use for diabetic ulcers
